Known targets — ChEMBL curated mechanism
CDK1CDK10CDK11BCDK12CDK13CDK14CDK15CDK16CDK17CDK18CDK19CDK2CDK20CDK3CDK4CDK5CDK6CDK7CDK8CDK9
The experimentally established mechanism targets of At-7519. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 known ✓ | Q00535 | 3/20 | 0.66 |
| ▸ | CDK9 known ✓ | P50750 | 2/20 | 0.66 |
| ▸ | CDK14 known ✓ | O94921 | 10/20 | 0.62 |
| ▸ | CDK2 known ✓ | P24941 | 7/20 | 0.62 |
| ▸ | CDK4 known ✓ | P11802 | 2/20 | 0.62 |
| ▸ | CDK1 known ✓ | P06493 | 2/20 | 0.62 |
| ▸ | CDK11B known ✓ | P21127 | 1/20 | 0.62 |
| ▸ | CDK7 known ✓ | P50613 | 1/20 | 0.62 |
| ▸ | CDK3 known ✓ | Q00526 | 1/20 | 0.62 |
| ▸ | CDK6 known ✓ | Q00534 | 1/20 | 0.62 |
| ▸ | CDK16 known ✓ | Q00536 | 1/20 | 0.62 |
| ▸ | CDK17 known ✓ | Q00537 | 1/20 | 0.62 |
| ▸ | CDK18 known ✓ | Q07002 | 1/20 | 0.62 |
| ▸ | CDK13 known ✓ | Q14004 | 1/20 | 0.62 |
| ▸ | CDK15 known ✓ | Q96Q40 | 1/20 | 0.62 |
| ▸ | CDK19 known ✓ | Q9BWU1 | 1/20 | 0.62 |
| ▸ | CDK12 known ✓ | Q9NYV4 | 1/20 | 0.62 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.66 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.66 |
| ▸ | CCNY | Q8ND76 | 10/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| At-7519 SCHEMBL955568 | 0.99 | CDK5 (0.67) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL31046986 | 0.98 | CDK5 (0.66) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL1069453 | 0.95 | CDK5 (0.62) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL1072294 | 0.94 | CDK5 (0.61) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| At-7519 SCHEMBL16318377 | 0.94 | CDK5 (0.61) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL8044614 | 0.93 | CDK5 (0.60) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL1286740 | 0.92 | CDK2 (0.67) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL1286739 | 0.88 | CDK5 (0.53) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL13993691 | 0.87 | CDK5 (0.52) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL13993707 | 0.87 | CDK5 (0.52) | CDK5CCNT1CDK9CDK5R1CDK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| CN-105263950-A | Stapling eif4e interacting peptides | AGENCY SCIENCE TECH & RES | 2016-01-20 | — | — | CN | claimed |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-03 | — | — | US | claimed |
| CN-114008058-B | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-111848579-B | Prodrugs of 4- (2, 6-dichlorobenzoylamino) -N- (4-piperidinyl) -1H-pyrazole-3-carboxamide | 君实润佳(上海)医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-11319344-B2 | Non-membrane disruptive P53 activating stapled peptides | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-05-03 | — | — | US | disclosed |
| CN-114008058-A | Prodrugs of CDK inhibitors for the treatment of cancer | 润佳（苏州）医药科技有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-01-18 | — | — | US | disclosed |
| CN-107531759-B | Non-membrane disruptive p 53-activated stapled peptides | 新加坡科技研究局 | 2021-11-16 | — | — | CN | disclosed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077426-A2 | 4- (2, 6-DICHLOROBENZOYLAMINO) -lH-PYRAZOLE-3 -CARBOXYLIC ACID PIPERIDIN- 4 -YLAMID ACID ADDITION SALTS AS KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077419-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077416-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| WO-2006077414-A1 | PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | disclosed |
| EP-1651612-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | Astex Therapeutics Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CDK5 26/4885CDK9 7/4885CDK14 25/4885 |
| US-11319344-B2 | Non-membrane disruptive P53 activating stapled peptides | TP53, ANXA3, ANXA2 | CDK5 4042/4885CDK9 4446/4885CDK14 3356/4885 |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CDK5 26/4885CDK9 7/4885CDK14 25/4885 |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CDK5 26/4885CDK9 7/4885CDK14 25/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | CDK5 1427/4885CDK9 2458/4885CDK14 1528/4885 |
| US-20150246946-A1 | PEPTIDES AND METHODS FOR TREATING CANCER | TP53, MDM4, MDM2 | CDK5 749/4885CDK9 595/4885CDK14 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.